Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows - USD ($)		3 Months Ended
		Mar. 31, 2016		Mar. 31, 2015
Cash flow from operating activities:
Net loss		$ (1,269,151)		$ (1,806,405)
Adjustments to reconcile net loss to net cash used in operations
Stock based compensation				$ 1,273,670
Accretion expense	[1]	73,572
Change in fair value of derivative liabilities		618,959	[2]
Changes in operating assets and liabilities:
Harmonized sales tax recoverable		9,483		$ (4,754)
Accounts payable and accrued liabilities		21,656		(48,644)
Deposits and other receivables		(6,030)
Net Cash used in operating activities		(551,511)		(586,133)
Cash flows from financing activities:
Proceeds from exercise of warrants				235,379
Proceeds from issuance of convertible promissory notes		175,000
Due from shareholders		50,724
Net Cash provided by financing activities		225,724		235,379
Net decrease in cash during the period		(325,787)		(350,754)
Effect of foreign currency translation		(31,171)		37,450
Cash, beginning of period		410,601		448,599
Cash, end of period		$ 53,643		$ 135,295

[1] See Note 7

[2] See Note 8